Published in Future Virol on January 01, 2009
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science (1988) 27.01
CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83
VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet (1964) 14.21
Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol (2007) 11.48
Epstein-Barr virus: 40 years on. Nat Rev Cancer (2004) 9.70
Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature (1989) 7.60
Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell (1991) 7.40
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A (1989) 6.32
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell (1995) 5.97
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med (2004) 5.61
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet (1991) 4.76
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif (2003) 4.68
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol (1990) 4.24
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol (1993) 4.05
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer (1988) 4.03
Early events in Epstein-Barr virus infection of human B lymphocytes. Virology (1991) 3.60
Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A (1997) 3.31
Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc Natl Acad Sci U S A (1990) 3.29
Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc Natl Acad Sci U S A (1995) 3.28
A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J Virol (1987) 3.10
Epstein-Barr virus mRNAs produced by alternative splicing. Nucleic Acids Res (1986) 2.94
Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol (1999) 2.82
Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol (2006) 2.79
Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol (2001) 2.77
Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity (1995) 2.74
Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science (1999) 2.61
B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol (2003) 2.57
Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol (1995) 2.25
Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol (1992) 2.14
T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. Cell Immunol (1984) 2.01
EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci U S A (1993) 1.99
5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael. J Virol (1989) 1.99
The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol (1996) 1.97
Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator. J Virol (1995) 1.92
Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell (2005) 1.92
Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol (1999) 1.92
NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med (1993) 1.92
Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci U S A (1995) 1.89
The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc Natl Acad Sci U S A (2003) 1.75
Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J Virol (1999) 1.70
New insights into cyclins, CDKs, and cell cycle control. Semin Cell Dev Biol (2005) 1.70
The tumor suppressor p53: cancer and aging. Cell Cycle (2008) 1.66
A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jkappa. J Virol (1996) 1.65
Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene (2007) 1.62
Expression of recombination activating genes (RAG-1 and RAG-2) in Epstein-Barr virus-bearing B cells. Blood (1995) 1.61
Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci (2008) 1.59
The cell cycle: a review. Vet Pathol (1998) 1.57
Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus. Cancer Res (2003) 1.56
Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J Virol (1992) 1.55
Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene (1996) 1.52
Complete genomic sequence of an Epstein-Barr virus-related herpesvirus naturally infecting a new world primate: a defining point in the evolution of oncogenic lymphocryptoviruses. J Virol (2002) 1.50
Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol (1997) 1.49
The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability. Front Biosci (2008) 1.48
Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci U S A (2005) 1.45
Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol (2003) 1.43
Modulation of histone acetyltransferase activity through interaction of epstein-barr nuclear antigen 3C with prothymosin alpha. Mol Cell Biol (2000) 1.41
Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. J Virol (1996) 1.41
Simian homologues of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci (2001) 1.40
Characterization of DP103, a novel DEAD box protein that binds to the Epstein-Barr virus nuclear proteins EBNA2 and EBNA3C. J Biol Chem (1999) 1.37
Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2. J Virol (2002) 1.33
Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci U S A (2006) 1.33
Epstein-Barr virus (EBV) nuclear antigen 6 induces expression of the EBV latent membrane protein and an activated phenotype in Raji cells. J Gen Virol (1993) 1.33
RB, the conductor that orchestrates life, death and differentiation. Oncogene (2006) 1.32
Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells. Immunology (1991) 1.30
The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol (2000) 1.30
Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci U S A (2006) 1.26
CtBP family proteins: more than transcriptional corepressors. Bioessays (2003) 1.26
Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J Virol (2001) 1.25
Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity. J Virol (2004) 1.21
The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer (1994) 1.20
Malignant transformation of B lymphoma cell line BJAB by Epstein-Barr virus-encoded small RNAs. FEBS Lett (2000) 1.19
Prediction and demonstration of a novel Epstein-Barr virus nuclear antigen. Nucleic Acids Res (1988) 1.18
Electron microscopic evidence for replication of circular Epstein-Barr virus genomes in latently infected Raji cells. J Virol (1984) 1.18
SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol (2005) 1.17
EBNA3C coactivation with EBNA2 requires a SUMO homology domain. J Virol (2004) 1.12
A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. J Virol (2004) 1.10
Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol (2008) 1.08
EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. Semin Cancer Biol (2001) 1.08
Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells. J Virol (2006) 1.07
Fifteen years of prothymosin alpha: contradictory past and new horizons. Peptides (2000) 1.03
The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J Virol (2007) 1.02
Epstein-Barr nuclear antigen-3 and -4 interact with RBP-2N, a major isoform of RBP-J kappa in B lymphocytes. Virology (1996) 1.02
EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes. Proc Natl Acad Sci U S A (2008) 1.01
Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cells. J Gen Virol (2005) 0.98
The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene (2004) 0.98
EBNA-LP associates with cellular proteins including DNA-PK and HA95. J Virol (2001) 0.95
Prothymosin alpha functions as a cellular oncoprotein by inducing transformation of rodent fibroblasts in vitro. J Biol Chem (2000) 0.95
Epstein-Barr virus. Virus Res (2002) 0.94
Biophysical and mutational analysis of the putative bZIP domain of Epstein-Barr virus EBNA 3C. J Virol (2004) 0.88
A license to kill: transcriptional activation and enhanced turnover of Myc by the SCF(kp2) ubiquitin ligase. Cancer Cell (2003) 0.86
Epstein-Barr virus and human T-cell lymphomas. Semin Cancer Biol (1996) 0.84
Identification of the nuclear localization signals within the Epstein-Barr virus EBNA-6 protein. J Gen Virol (2004) 0.84
The Epstein-Barr virus nuclear antigen-6 protein co-localizes with EBNA-3 and survival of motor neurons protein. Virology (2004) 0.80